The Latest Research on CDK 4/6 Inhibitors
Learn about new CDK 4/6 inhibitor research in different breast cancer subtypes, including HER2+ and triple-negative MBC.
Why You Should Consider Repeat Biopsies
Learn about the importance of repeat biopsies and how they affect treatment decisions and clinical trial eligibility.
Oncolytic Viruses: Using Viruses to Kill Cancer Cells
Learn how oncolytic viruses work and how to find MBC clinical trials studying this new type of treatment.
Why Knowing Your HER2 Status is Important
Did you know your HER2 status may change over time? Knowing your HER2 status is important to select the best MBC treatment. Learn more here.
Triple-Negative Metastatic Breast Cancer: Beyond ER, PR, and HER2
Click to learn about biomarkers and targeted therapies for triple-negative MBC.
Update on Immunotherapy for MBC: Immune Checkpoint Inhibitors
Read about immune checkpoint inhibitors approved and in clinical trials for MBC.
Update On Antibody-Drug Conjugates (ADCs) For MBC
Antibody-drug conjugates consist of an antibody attached to a chemotherapy drug that delivers chemotherapy only where it is needed, limiting unwanted side effects. ADCs work by combining the ability of antibodies to target cancer cells with the ability of chemotherapy drugs to kill cancer cells.
Three ADCs are approved for MBC: ado-trastuzumab emtansine (Kadcyla®) for HER2+ MBC, fam-trastuzumab deruxtecan (Enhertu®) for HER2+ MBC, and sacituzumab govitecan-hziy (Trodelvy®) for triple-negative MBC. Others are being tested in clinical trials.
Read below for general information about how ADCs work, a recent comparison of the two ADCs for HER2+ MBC, and news about sacituzumab govitecan-hziy (Trodelvy®), the recently approved ADC for triple-negative MBC.
General Information About ADCs
- Roche (Video): What Are Antibody-Drug Conjugates And How Do They Work Against Cancer?
- Susan G. Komen: Emerging Areas In Metastatic Breast Cancer Treatment
ADCs For HER2+ MBC
- Targeted Oncology: Trastuzumab Deruxtecan Shows Efficacy Over T-DM1 In HER2+ Breast Cancer
- OncLive: ADC Treatment Options And Clinical Data In Breast Cancer
- Targeted Oncology: Trastuzumab Deruxtecan For HER2-Low Breast Cancer
ADC For Triple-Negative MBC
- FDA: FDA Approval Of Sacituzumab Govitecan For Triple-Negative MBC
- National Cancer Institute: Sacituzumab Granted Regular FDA Approval For TNBC
Clinical Trials That Include Antibody-Drug Conjugates
- Metastatic Trial Search: MBC Trials That Include Antibody-Drug Conjugates
- Solid Tumor Trials: Trials That May Include Antibody-Drug Conjugates
Bispecific Antibodies: An Emerging Class Of MBC Drugs
Learn about bispecific antibodies, which bind to two targets instead of one, for MBC treatment.
What do FGFR Genetic Mutations Mean for You and Your MBC?
Learn about FGFR and what genetic abnormalities in FGFR mean for you and your MBC.